Theoretical model proposes PET/MRI-guided nanoparticle delivery of enzymes and peptides in Alzheimer's disease, suggesting safe dual clearance of amyloid-beta and tau.
This theoretical paper introduces an innovative, dual-action nanomedicine strategy designed to address key limitations in current Alzheimer's disease therapeutics. By coupling PET/MRI-guided Focused Ultrasound (FUS) with smart, pH-responsive PEG-PLGA nanoparticles, the platform temporarily bypasses the blood-brain barrier without surgery. The system deploys two specialized nanoparticle formulations: one functionalized with conformation-specific ligands to release an engineered "Super-IDE" enzyme that cleaves extracellular amyloid-beta (Aβ42) plaques without triggering ARIA-inducing neuroinflammation, and a second formulation targeted via RVG29 to deliver cationic Cell-Penetrating Peptides (CPPs) directly into neurons. Inside the cytoplasm, these positive peptides electrostatically shield the dense negative phosphate clusters on hyperphosphorylated Tau, halting self-assembly and neurofibrillary tangle spreading. The study includes comprehensive in vitro and in vivo evaluation protocols alongside clinical translation guidelines to ensure safe, targeted, and non-inflammatory clearance of both hallmarks of Alzheimer's pathology.
No takes yet. Share an insight, caveat, or question.
Derin Kahya (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: